Radiation plus immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have an advanced solid tumor that has spread to between 3 and 10 places in your body (not counting the original tumor).
- You have been on an FDA-approved immunotherapy drug (like a PD-1 or PD-L1 inhibitor) for more than 3 months.
- Your cancer is either stable or has partially shrunk while on immunotherapy.
- You do not have active autoimmune disease, severe lung problems, or brain metastases that are large or causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
This study tests whether targeted radiation can help your immune system respond to immunotherapy again if your cancer has stopped responding. You would continue your current immunotherapy and receive a few focused radiation doses to one tumor site.
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.